PET predicts chemo success in non-small cell lung cancer patients

July 23, 2013

The predictive value of FDG PET for therapy response has been proven for a range of treatments for non-small cell lung cancer (NSCLC), now including concomitant chemoradiotherapy, which requires careful patient selection due to associated morbidity, according to a study published July 17 in the Journal of Nuclear Medicine.

Edwin A. Usmanij, from the department of nuclear medicine at Radboud University Nijmegen Medical Centre in Nijmegen, The Netherlands, and colleagues followed patients with locally advanced NSCLC as they underwent comcomitant regiments of dual-drug chemotherapy and intensity modulated radiotherapy. FDG PET was performed on all patients multiple times and predictive parameters including total lesion glycolysis (TLG) were calculated.